Last updated: August 9, 2026

ERYC Sprinkles is an erythromycin ethylsuccinate delayed-release capsule product used primarily when patients require oral macrolide therapy but cannot reliably swallow conventional tablets or capsules. Its commercial profile is defined by an old active ingredient, generic competition, limited differentiation, fragmented erythromycin demand, and the absence of publicly reported product-level revenue.

The product has little apparent patent or regulatory exclusivity. Its value is more likely tied to manufacturing continuity, pediatric and dysphagia-focused prescribing, distributor access, and supply reliability than to proprietary intellectual property.

What is ERYC Sprinkles and who markets it?

ERYC Sprinkles contains erythromycin ethylsuccinate, an oral prodrug of erythromycin. The delayed-release sprinkle formulation is intended for oral administration and can be useful for patients who have difficulty swallowing conventional solid dosage forms.

FDA labeling identifies ERYC as a delayed-release capsule product. The label covers antibacterial indications involving susceptible organisms, including selected respiratory-tract, skin, and soft-tissue infections. Erythromycin is also used in certain patients with penicillin allergy, although resistance patterns and guideline preferences limit its role in many indications. [1]

The product has historically been associated with Arbor Pharmaceuticals. Arbor later became part of Azurity Pharmaceuticals, a privately held company focused on specialty and pediatric medicines. Public company materials have not provided standalone revenue for ERYC Sprinkles. [2]

Attribute	ERYC Sprinkles
Active ingredient	Erythromycin ethylsuccinate
Therapeutic class	Macrolide antibiotic
Dosage form	Delayed-release sprinkle capsule
Primary differentiation	Administration format and delayed release
FDA pathway	Abbreviated New Drug Application or legacy NDA framework depending on product listing
Biosimilar exposure	None
Patent profile	No publicly visible composition-of-matter exclusivity
Commercial owner history	Arbor Pharmaceuticals; subsequently associated with Azurity Pharmaceuticals
Public product revenue	Not separately disclosed
Key commercial risk	Low-volume demand, generic competition, and supply continuity

What is the FDA regulatory status of ERYC Sprinkles?

ERYC Sprinkles is an FDA-regulated prescription erythromycin product. FDA labeling describes the product as a delayed-release capsule containing erythromycin ethylsuccinate. The regulatory value of the product lies in its approved formulation, manufacturing controls, labeling, and ability to remain available through the U.S. prescription market.

The FDA’s Orange Book is the controlling source for listed patents, therapeutic equivalence codes, and marketing status. Products with no current Orange Book patent listing do not receive the practical protection associated with an active listed patent and a corresponding Paragraph IV dispute. [3]

The available public regulatory record does not indicate meaningful remaining FDA exclusivity for ERYC Sprinkles. Any original approval exclusivity would have expired long before the current commercial period because erythromycin ethylsuccinate has been marketed for decades.

Is ERYC Sprinkles an NDA product or a generic product?

ERYC is a branded prescription product, but branded status does not establish patent protection. Older products can remain branded while competing products enter through abbreviated or other regulatory pathways.

The relevant commercial distinction is between:

The branded ERYC product;
Generic erythromycin ethylsuccinate products;
Other erythromycin dosage forms, including tablets, capsules, suspensions, and delayed-release products;
Alternative macrolides such as azithromycin and clarithromycin.

The product’s market position depends on its specific dosage form and availability rather than on active ingredient exclusivity.

When does ERYC Sprinkles lose exclusivity?

ERYC Sprinkles has no meaningful remaining regulatory exclusivity based on the age of erythromycin ethylsuccinate and the long commercial history of the active ingredient.

Exclusivity timeline

Exclusivity category	ERYC Sprinkles position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable based on the product’s principal antibacterial indications
Pediatric exclusivity	No current period identified
New clinical investigation exclusivity	No current period identified
Patent term extension	No current extension identified
Composition-of-matter patent	Expired or not applicable to the current commercial period
Formulation patent	No active, commercially material protection identified in public records
Method-of-use patent	No active, commercially material protection identified
Biosimilar exclusivity	Not applicable

The product therefore competes in an open market. A potential entrant would not need to wait for an active period of FDA exclusivity if it could satisfy the applicable regulatory, bioequivalence, manufacturing, and formulation requirements.

What patents protect ERYC Sprinkles?

No active patent estate with material commercial impact is apparent for ERYC Sprinkles.

Erythromycin ethylsuccinate is an established active ingredient. Any historic patents covering the molecule or early pharmaceutical uses would have expired. The remaining potential protection would have to come from a specific formulation, release mechanism, manufacturing process, capsule architecture, or use.

The commercial importance of those categories is limited:

Patent category	Expected relevance to ERYC Sprinkles
Active ingredient	Minimal; historic protection is expired
Delayed-release formulation	Potentially relevant only if an unexpired patent covers the exact dosage form
Sprinkle delivery format	Potentially relevant, but no active high-value estate is publicly apparent
Manufacturing process	Could create operational barriers but would not necessarily block a design-around
Method of treatment	Low relevance for an established antibiotic with broad historical use
Packaging or device	Limited relevance because the product is an oral capsule
Trade secret	Possible manufacturing value, but not publicly enforceable as a patent barrier

The absence of a strong patent estate changes the competitive question. A challenger would focus less on Paragraph IV litigation and more on whether it could manufacture an equivalent delayed-release sprinkle product at a sustainable cost.

Are there Paragraph IV challenges to ERYC Sprinkles?

No major, publicly prominent Paragraph IV litigation is associated with ERYC Sprinkles in the available record.

Paragraph IV litigation generally arises when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. The absence of a material current Orange Book patent listing substantially reduces the probability of a conventional Paragraph IV dispute.

A competitor could still face regulatory and technical hurdles, including:

Demonstrating bioequivalence for a delayed-release product;
Matching the drug-release profile;
Establishing stability across the product shelf life;
Controlling particle size and dose uniformity;
Proving capsule-opening or sprinkle-administration performance where relevant;
Establishing manufacturing consistency.

Those hurdles can delay entry without creating patent exclusivity.

What formulations are protected by ERYC Sprinkles?

The formulation’s commercial differentiation is the combination of erythromycin ethylsuccinate, delayed release, and sprinkle administration. That combination may be difficult to reproduce precisely, but technical difficulty is not equivalent to patent protection.

The key formulation attributes are:

Protection of erythromycin ethylsuccinate from premature degradation;
Delayed release designed to reduce release in the stomach;
Uniform distribution of active pharmaceutical ingredient;
Administration flexibility for patients unable to swallow conventional dosage forms;
Stability during storage and handling.

The product competes against liquid erythromycin suspensions, immediate-release solid dosage forms, and other macrolide formulations. Its clinical value is concentrated in patients for whom dosage-form flexibility matters. That is a narrower market than the broader oral macrolide market.

How strong is the patent estate for ERYC Sprinkles?

The patent estate is weak from a market-exclusion perspective.

Patent-strength assessment

Factor	Assessment	Commercial effect
Active ingredient protection	Very weak or expired	Does not block generic erythromycin
Formulation protection	Limited public evidence	May create technical entry work, not durable exclusivity
Method-of-use protection	Weak	Broad antibacterial uses are established
Orange Book leverage	Limited	Low likelihood of a patent-based delay
Manufacturing know-how	Potentially moderate	Can affect cost and supply reliability
Litigation deterrence	Low	Limited incentive for high-cost patent challenges
Substitution protection	Low to moderate	Prescribers can use other erythromycin forms or macrolides

The product may still have a defensible niche if competitors cannot achieve sufficient manufacturing economics. That is an operational moat, not a classic patent moat.

What is the competitive landscape for ERYC Sprinkles?

ERYC Sprinkles competes in two overlapping markets: erythromycin products and oral macrolide antibiotics.

Direct and indirect competitors

Competitor class	Examples	Competitive relationship
Erythromycin ethylsuccinate liquids	E.E.S., EryPed and equivalent suspensions	Compete for pediatric and swallowing-limited patients
Erythromycin tablets and capsules	Generic erythromycin products	Compete on active ingredient and price
Delayed-release erythromycin products	Equivalent or similar solid dosage forms	Closest potential substitutes
Azithromycin	Zithromax and generics	Strong substitute because of dosing convenience
Clarithromycin	Biaxin and generics	Substitute in selected respiratory and infectious indications
Other antibiotics	Amoxicillin, cephalosporins, clindamycin and others	Compete based on organism, indication and resistance

Azithromycin has a substantial commercial advantage in many settings because of convenient dosing and broad prescribing familiarity. Generic erythromycin retains use where clinicians value historical experience, specific susceptibility, pregnancy-related considerations, or macrolide alternatives.

Erythromycin’s gastrointestinal tolerability and drug-interaction profile can restrict demand. Resistance also reduces use in some infections. The product therefore operates in a mature, price-sensitive market rather than a growth category.

What are the market dynamics for ERYC Sprinkles?

ERYC Sprinkles is likely a low-volume specialty product with relatively high dependence on channel execution.

The primary market drivers are:

Pediatric prescribing;
Patients with swallowing limitations;
Availability of alternative oral antibiotic formulations;
Hospital and retail pharmacy stocking decisions;
Generic price competition;
Shortages affecting other erythromycin presentations;
Prescriber familiarity with delayed-release sprinkle administration.

The product’s demand is probably episodic. Antibiotics are not chronic therapies, so revenue depends on prescription volume, seasonality, infection incidence, and distributor inventory.

A supply interruption can have an outsized effect because alternative dosage forms may not be interchangeable in practice. Conversely, a competitor with reliable supply could capture volume quickly because prescribers face limited switching costs once an equivalent administration option is available.

What is the financial trajectory of ERYC Sprinkles?

Public financial disclosures do not report ERYC Sprinkles revenue, gross margin, prescription volume, or profitability separately. Arbor Pharmaceuticals was privately held, and Azurity Pharmaceuticals does not publish product-level financial statements for ERYC Sprinkles.

The likely financial trajectory is mature to declining, with periodic revenue volatility caused by supply conditions and product availability rather than underlying market expansion.

Revenue trajectory factors

Period	Likely financial condition	Main drivers
Early commercial period	Protected or branded pricing	Limited competition and product novelty
Mature branded period	Volume erosion	Generic erythromycin and alternative macrolides
Current specialty period	Low and concentrated revenue	Narrow patient segment and limited dosage-form differentiation
Supply-constrained periods	Temporary revenue spikes possible	Shortages or discontinuations affecting substitutes
Long-term outlook	Flat to declining base case	No visible exclusivity catalyst and mature antibiotic demand

Potential revenue-supporting factors include limited competition for the exact sprinkle presentation, brand recognition among pediatric prescribers, and the practical value of a delayed-release dosage form.

Revenue pressure comes from low-priced erythromycin alternatives, reduced erythromycin prescribing, manufacturing complexity, and the absence of a patent-based price umbrella. The product is unlikely to support blockbuster economics unless it benefits from a broader portfolio strategy, shortage-related pricing, or a highly defensible supply position.

Does ERYC Sprinkles have biosimilar risk?

No. Biosimilar risk does not apply because ERYC Sprinkles is a small-molecule erythromycin product, not a biologic.

The relevant competitive threats are generic substitution, alternative erythromycin dosage forms, and therapeutic substitution to other macrolides or antibiotics. Regulatory competition would occur through generic drug pathways rather than the biosimilar pathway.

What generic entry risks exist for ERYC Sprinkles?

Generic entry risk is structurally high because the active ingredient is old and patent protection is not a significant barrier.

The main entry constraints are technical:

Matching delayed-release dissolution;
Demonstrating bioequivalence;
Reproducing sprinkle performance;
Maintaining content uniformity;
Managing taste, stability and capsule-opening characteristics;
Achieving acceptable manufacturing economics at low annual volume.

A generic entrant may avoid direct competition if the addressable market is too small. That can preserve the branded product’s commercial position even without patents. The most likely competitive scenario is incremental entry by a limited number of manufacturers rather than a large wave of applicants.

What patent litigation, licensing deals, or settlements affect ERYC Sprinkles?

No major public patent litigation, Paragraph IV settlement, or licensing transaction specifically tied to ERYC Sprinkles is apparent.

The most relevant corporate transaction is Arbor Pharmaceuticals’ acquisition by KKR-backed Azurity Pharmaceuticals. That transaction placed Arbor’s portfolio, including legacy specialty and pediatric products, within Azurity’s commercial platform. It was a corporate portfolio transaction rather than a publicly disclosed ERYC-specific licensing arrangement. [2]

The lack of public settlement activity is consistent with a product that has limited active patent leverage and modest commercial scale.

What generic launch scenarios are most likely?

Scenario 1: No direct generic launch

This is plausible if the market is too small to justify formulation development, bioequivalence work, and commercial distribution. ERYC could retain a niche position despite weak intellectual property.

Scenario 2: One technically capable generic entrant

A single entrant could pressure price and volume while leaving the branded product with residual demand from prescribers and pharmacies that value continuity.

Scenario 3: Multiple entrants

Multiple generic manufacturers would likely produce substantial price erosion. The impact would depend on whether the product is automatically substitutable and whether the generic matches the same delayed-release sprinkle presentation.

Scenario 4: Substitution through other dosage forms

Liquid erythromycin, conventional erythromycin products, azithromycin, and clarithromycin may capture demand without a direct ERYC-equivalent launch. This is the most persistent competitive pressure because therapeutic substitution does not require duplicating the exact formulation.

What is the geographic coverage of ERYC Sprinkles?

The principal commercial opportunity is the United States, where the product’s FDA-approved labeling and distribution infrastructure apply. There is no established evidence of a broad international franchise under the ERYC Sprinkles name.

Geographic expansion would require country-specific approval, local labeling, manufacturing compliance, reimbursement access, and distribution. Those requirements are difficult to justify for a mature antibiotic dosage form unless a partner has an established pediatric or specialty-pharmacy platform.

Key Takeaways

ERYC Sprinkles is an erythromycin ethylsuccinate delayed-release sprinkle capsule.
Its value comes from dosage-form convenience and supply continuity, not from a strong active patent estate.
FDA exclusivity and any original molecule-level patent protection are long expired.
No major current Paragraph IV litigation, patent settlement, or product-specific licensing dispute is publicly apparent.
Biosimilar competition is irrelevant; the key risks are generic entry and therapeutic substitution.
Product-level revenue and profitability are not publicly disclosed.
The likely financial profile is mature, low-volume, and vulnerable to price erosion.
The strongest commercial defense is manufacturing reliability and niche prescribing demand.
Azithromycin, clarithromycin, liquid erythromycin, and generic erythromycin products limit long-term growth.
A direct generic entrant could pressure price, but the small market may deter multiple competitors.

FAQs

Is ERYC Sprinkles still commercially available?

Availability can vary by wholesaler, pharmacy and manufacturer inventory. The product’s commercial status should be distinguished from FDA approval status because a product may remain approved while experiencing intermittent distribution or marketing changes.

Can pharmacies automatically substitute a generic for ERYC Sprinkles?

Substitution depends on the FDA therapeutic-equivalence rating, the exact dosage form, state pharmacy law, and whether the generic matches the delayed-release sprinkle presentation. A conventional erythromycin tablet or liquid is not automatically equivalent to a delayed-release sprinkle capsule.

Why would ERYC Sprinkles retain value without patents?

A niche product can retain value when it solves an administration problem, has established prescriber recognition, and faces limited competition because the market is too small to attract many manufacturers.

What would most improve ERYC Sprinkles’ financial outlook?

The strongest potential drivers would be reliable supply during competitor shortages, expanded pediatric distribution, improved reimbursement, and a differentiated formulation that reduces administration or tolerability problems.

Is ERYC Sprinkles exposed to antibiotic-resistance trends?

Yes. Resistance can reduce prescribing in susceptible indications. Broader stewardship initiatives and the availability of newer or more convenient antibiotics also constrain demand.

References

U.S. Food and Drug Administration. (n.d.). ERYC: Erythromycin ethylsuccinate delayed-release capsules prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
Azurity Pharmaceuticals. (2021). Azurity Pharmaceuticals completes acquisition of Arbor Pharmaceuticals. https://azurity.com/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	10
Patent Applications:	3,740
DailyMed Link:	ERYC SPRINKLES at DailyMed

Sponsor	Phase
Vanderbilt University Medical Center	Phase 2
St. Jude Children's Research Hospital	Phase 2
Simbec Research	Phase 1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	ERYC SPRINKLES	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	050593-001	Jul 22, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for ERYC SPRINKLES

Recent Clinical Trials for ERYC SPRINKLES